Porsolt SAS, a long established preclinical screening, efficacy, and safety CRO, has completed a significant expansion of its research facility, adding a further 5,500 sq.ft. of experimental space.
The expansion integrates Porsolt's new areas of research, cutting edge technologies, increased in vitro capabilities, and growing portfolio of preclinical models. This enhances Porsolt's ability to employ predictive tools, including cell-based models, to meet the requirements of the pharmaceutical and biotech industries and optimize drug discovery pipelines.
The additional research space comprises in vitro laboratories including cell culture, flow cytometry, histology, imaging, and analysis, that have been incorporated from Fluofarma. Porsolt has also expanded its chemistry, biochemistry, biomarker, ex-vivo capabilities, and housing capacity for in vivo studies.
"This is reflective of the consistent growth of Porsolt SAS over recent years, incorporating new areas of research and specialized expertise,"
